Radiofrequency Ablation/Bone Augmentation + Radiotherapy vs Radiotherapy Alone

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a single-center, randomized controlled pilot study of radiofrequency ablation and bone augmentation (RFA/BA) plus radiotherapy (RT) vs. RT alone in patients with metastatic T5-L5 disease of the spine. Patients will be randomized 2:1 to receive either one treatment of RFA/BA plus RT or RT to evaluate the occurrence of skeletal-related events. Skeletal-related events (SREs) are defined as new clinical or radiologic evidence of pathologic fracture, spinal cord or nerve root compression, pain or instability, and/or necessity for additional local intervention (i.e. surgery, repeat RFA/BA or RT) due to persistent or progressive symptoms. Post-treatment follow-up for SREs are assessed at 1, 3, 6, 12, and 24 months.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Histologically confirmed metastatic T5-L5 disease of the spine (with up to two levels) as detected by any imaging study.

• Have either associated bone pain or cross-sectional imaging characteristics that are predictors of SRE.

• Age 18 years of age or older at the time of consent.

• Have adequate organ function confirmed by the following laboratory values obtained within 14 days prior to study enrollment defined as:

‣ absolute neutrophil count (ANC) ≥ 1.5 × 109/L

⁃ platelets ≥ 50 × 109/L

⁃ hemoglobin ≥ 10 g/dL, independent of transfusion ≤14 days of screening

⁃ aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); if liver metastases, then ≤ 5 × ULN

⁃ total bilirubin ≤ 1.5 × ULN; \< 2 × ULN if hyperbilirubinemia is due to Gilbert's syndrome

⁃ serum albumin ≥ 30 g/L (3.0 g/dL)

⁃ serum creatinine ≤ 1.5 x ULN; OR estimated glomerular filtration rate (GFR) ≥ 45 mL/min using the Cockcroft Gault formula

• Persons of childbearing potential (POCB) or with partners of childbearing potential must be willing to use contraception during study treatment and 6 months after study treatment.

• Persons are considered to be of childbearing potential unless one or the following applies:

‣ Is postmenopausal, defined as no menses for at least 12 months without an alternative medical cause

⁃ Considered permanently sterile. Permanent sterilization includes hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy

• Voluntary written consent prior to the performance of any research related activity

Locations
United States
Minnesota
University of Minnesota
RECRUITING
Minneapolis
Contact Information
Primary
Surgery Clinical Trials Office
surgCTO@umn.edu
612-624-7463
Time Frame
Start Date: 2025-12-01
Estimated Completion Date: 2028-06-13
Participants
Target number of participants: 36
Treatments
Active_comparator: Radiofrequency ablation and bone augmentation with radiotherapy
Radiofrequency-generated heat to eradicate cancer cells, followed by the application of a bone-stabilizing agent to offer both tumor control and structural reinforcement. Radiotherapy (RT) uses high-energy radiation to target and destroy cancer cells, providing notable pain relief and potentially reducing tumor size
Placebo_comparator: Radiotherapy alone
ONLY uses high-energy radiation to target and destroy cancer cells, providing notable pain relief and potentially reducing tumor size
Related Therapeutic Areas
Sponsors
Leads: University of Minnesota

This content was sourced from clinicaltrials.gov